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Abstract
Background
In sub-Saharan Africa, individuals infected with HIV who are severely immunocompromised
have high mortality (about 10%) shortly after starting antiretroviral therapy (ART). This
group also has the greatest risk of morbidity and mortality associated with immune reconsti-
tution inflammatory syndrome (IRIS), a paradoxical response to successful ART. Integrase
inhibitors lead to significantly more rapid declines in HIV viral load (VL) than all other ART
classes. We hypothesised that intensifying standard triple-drug ART with the integrase
inhibitor, raltegravir, would reduce HIV VL faster and hence reduce early mortality, although
this strategy could also risk more IRIS events.
Methods and findings
In a 2×2×2 factorial open-label parallel-group trial, treatment-naive adults, adolescents, and
children >5 years old infected with HIV, with cluster of differentiation 4 (CD4) <100 cells/
mm3, from eight urban/peri-urban HIV clinics at regional hospitals in Kenya, Malawi,
Uganda, and Zimbabwe were randomised 1:1 to initiate standard triple-drug ART, with or
without 12-week raltegravir intensification, and followed for 48 weeks. The primary outcome
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was 24-week mortality, analysed by intention to treat. Of 2,356 individuals screened for eligi-
bility, 1,805 were randomised between 18 June 2013 and 10 April 2015. Of the 1,805 partici-
pants, 961 (53.2%) were male, 72 (4.0%) were children/adolescents, median age was 36
years, CD4 count was 37 cells/mm3, and plasma viraemia was 249,770 copies/mL. Fifty-six
participants (3.1%) were lost to follow-up at 48 weeks. By 24 weeks, 97/902 (10.9%) ralte-
gravir-intensified ART versus 91/903 (10.2%) standard ART participants had died (adjusted
hazard ratio [aHR] = 1.10 [95% CI 0.82–1.46], p = 0.53), with no evidence of interaction with
other randomisations (pheterogeneity > 0.7) and despite significantly greater VL suppression
with raltegravir-intensified ART at 4 weeks (343/836 [41.0%] versus 113/841 [13.4%] with
standard ART, p < 0.001) and 12 weeks (567/789 [71.9%] versus 415/803 [51.7%] with
standard ART, p < 0.001). Through 48 weeks, there was no evidence of differences in mor-
tality (aHR = 0.98 [95% CI 0.76–1.28], p = 0.91); in serious (aHR = 0.99 [0.81–1.21], p =
0.88), grade-4 (aHR = 0.88 [0.71–1.09], p = 0.29), or ART-modifying (aHR = 0.90 [0.63–
1.27], p = 0.54) adverse events (the latter occurring in 59 [6.5%] participants with raltegravir-
intensified ART versus 66 [7.3%] with standard ART); in events judged compatible with IRIS
(occurring in 89 [9.9%] participants with raltegravir-intensified ART versus 86 [9.5%] with
standard ART, p = 0.79) or in hospitalisations (aHR = 0.94 [95% CI 0.76–1.17], p = 0.59). At
12 weeks, one and two raltegravir-intensified participants had predicted intermediate-level
and high-level raltegravir resistance, respectively. At 48 weeks, the nucleoside reverse tran-
scriptase inhibitor (NRTI) mutation K219E/Q (p = 0.004) and the non-nucleoside reverse
transcriptase inhibitor (NNRTI) mutations K101E/P (p = 0.03) and P225H (p = 0.007) were
less common in virus from participants with raltegravir-intensified ART, with weak evidence
of less intermediate- or high-level resistance to tenofovir (p = 0.06), abacavir (p = 0.08), and
rilpivirine (p = 0.07). Limitations of the study include limited clinical, radiological, and/or
microbiological information for some participants, reflecting available services at the cen-
tres, and lack of baseline genotypes.
Conclusions
Although 12 weeks of raltegravir intensification was well tolerated and reduced HIV viraemia
significantly faster than standard triple-drug ART during the time of greatest risk for early
death, this strategy did not reduce mortality or clinical events in this group and is not war-
ranted. There was no excess of IRIS-compatible events, suggesting that integrase inhibitors
can be used safely as part of standard triple-drug first-line therapy in severely immunocom-
promised individuals.
Trial registration
ClinicalTrials.gov NCT01825031.
Trial registration
International Standard Randomised Controlled Trials Number ISRCTN 43622374.
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Author summary
Why was this study done?
• Individuals in Africa who are HIV positive and initiating treatment with severe immu-
nosuppression (CD4 < 100 cells/mm3) have high risks of dying shortly after starting
treatment.
• It would be expected that adding an integrase inhibitor (raltegravir) to standard triple-
drug antiretroviral therapy for 12 weeks would reduce HIV viral load faster: we wanted
to find out whether this would reduce high early mortality.
What did the researchers do and find?
• We randomly allocated 1,805 adults, adolescents, and older children to receive standard
antiretroviral therapy with or without 12 weeks of adjunctive raltegravir.
• We found that the group receiving 12 weeks of adjunctive raltegravir had significantly
faster declines in HIV viral load.
• However, we found no significant difference in deaths within 24 weeks of starting treat-
ment between those receiving adjunctive raltegravir (97/902 [10.9%]) or not (91/903
[10.2%]); nor were there differences in clinical disease progression, immune reconstitu-
tion, inflammatory syndrome, or adverse events.
What do these findings mean?
• In this study, we found that intensifying the potency of initial antiretroviral therapy did
not reduce early mortality on treatment, providing no support for its widespread use in
individuals initiating treatment with severe immunosuppression.
• However, it also did not increase the rates of clinically important immune reconstitu-
tion inflammatory syndrome, suggesting that integrase inhibitors could replace other
components of standard first-line antiretroviral therapy safely.
Introduction
Despite World Health Organisation (WHO) guidelines recommending universal antiretroviral
therapy (ART) regardless of cluster of differentiation 4 (CD4) cell count [1], 20%–25% of indi-
viduals infected with HIV in sub-Saharan Africa continue to present for care with severe
immunosuppression (CD4 count< 100 cells/mm3) [2]. Of these, about 10% die in the first 3
months after ART initiation [3–6]. Causes of early death are multifactorial and are similar for
adults and older children [5]. Possible strategies to reduce this excess mortality could aim to
accelerate immune restoration by controlling HIV viraemia more rapidly; to control or pre-
vent overt clinical infections; or to provide nutritional support to enhance immune response
to infection and reverse metabolic deficiencies.
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Standard WHO-recommended ART [1] consists of two nucleos(t)ide reverse transcriptase
inhibitors (N(t)RTI), with a non-nucleoside reverse transcriptase inhibitor (NNRTI). Another
key drug class is integrase strand-transfer inhibitors (INSTIs), which result in faster decline in
HIV viral load (VL) over the first 3 months of combination therapy [7,8]. Several studies have
investigated how this might impact chronic inflammation and immune restoration; in some,
INSTIs appeared to improve markers of inflammation (including microbial translocation)
and/or T-cell activation [9–14], but in others there were no clear differences in inflammatory
and other markers (i.e., D-dimer, interleukin 6 [IL-6], and T-cell activation) [15]. The clinical
importance of intensified or quadruple ART in patients with VL>100,000 copies/mL or
advanced disease remains unclear.
To our knowledge, no randomised trial has been powered to test the hypothesis that the
INSTI-associated rapid reduction in HIV viraemia translates into clinical benefit, mortality
reductions in particular, or, conversely, is associated with harm through increased risk of
immune reconstitution inflammatory syndrome (IRIS). We therefore conducted the Reduc-
tion of EArly mortaLITY (REALITY) randomised clinical-endpoint trial (NCT01825031;
ISRCTN43622374) to compare three interventions to reduce early mortality in adults and
older children initiating ART with CD4<100 cells/mm3 in four sub-Saharan African coun-
tries: adjunctive intensification with raltegravir [16] (the first licenced INSTI), enhanced anti-
infective prophylaxis, and food supplementation. Here, we report on the impact of adjunctive
raltegravir intensification.
Materials and methods
Adults, adolescents, and children aged�5 years infected with HIV, diagnosed through
national screening programmes, not on ART and reporting no previous ART, and with CD4
<100 cells/mm3 were approached consecutively for screening from inpatient and outpatient
facilities at clinics at eight urban/peri-urban regional hospitals in Zimbabwe, Uganda, Malawi,
and Kenya. When CD4 counts were not routinely performed at diagnosis, those with new HIV
diagnoses were approached consecutively for CD4 testing and study screening. Participants
were enrolled if they had screening CD4 count<100 cells/mm3, were ART-naive, were not
pregnant/breastfeeding, had not used single-dose nevirapine to prevent mother-to-child trans-
mission, had no contraindications to trial drugs, and provided written informed consent. The
trial was approved by Ethics Committees in Zimbabwe, Uganda, Malawi, Kenya, and the
United Kingdom. The protocol and CONSORT checklist are provided as S1 Protocol and S1
CONSORT checklist.
Participants were randomised 1:1 to initiate open-label ART with 2NRTI+NNRTI either
alone (standard ART) or with 12 weeks’ raltegravir (raltegravir intensification) using standard
doses (see S1 Text). Standard ART was tenofovir-disoproxil-fumarate+emtricitabine or zido-
vudine+lamivudine in adults and adolescents and abacavir+lamivudine or zidovudine+-
lamivudine in children aged 5–<13 years, with nevirapine or efavirenz, according to physician
choice and local standard of care. Participants were also factorially randomised 1:1 to 12 weeks
enhanced anti-infection prophylaxis versus standard-of-care co-trimoxazole prophylaxis [17],
and 1:1 to 12 weeks ready-to-use supplementary food (RUSF) versus no routine supplementa-
tion [18] (see S1 Text for details).
Randomisation was stratified by centre, age (</�13 years), and the other factorial rando-
misations. A computer-generated sequential randomisation list using variably sized permuted
blocks was prepared by the trial statistician and incorporated securely into the online trial
database. The list was concealed until allocation after eligibility was confirmed by local centre
staff, who then performed the randomisation.
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Nurse visits at weeks 2, 4, 8, 12, 18, 24, 36, and 48 included symptom checklist, self-reported
adherence assessment (with standard adherence support), medication dispensing, and body
composition assessment using bioimpedance (TANITA BC-420MA). At weeks 4, 12, 24, 36,
and 48, history and examination were undertaken by a physician; haematology, biochemistry,
and CD4/CD8 assays were performed at local laboratories; and plasma was stored for retro-
spective VL and genotyping (results not available in real time). Nurses/physicians were
unblinded. Laboratory tests were assayed blind to randomisation. Toxicity substitution and/or
second-line switch were at physician discretion, following WHO guidelines [19]. Participants
exited the trial after 48 weeks. Consent was obtained to ascertain vital status in all participants
at trial closure (May 2016, i.e., beyond 48 weeks from randomisation) from the ART pro-
grammes where they had transferred to care at trial exit.
The primary outcome was all-cause mortality to 24 weeks. Secondary outcomes to 48 weeks
were all-cause mortality; serious adverse events (SAEs) following International Committee on
Harmonization definitions, grade-4 adverse events (AEs), and AEs leading to modification of
ART/trial drugs; specific mechanisms of each intervention (CD4 count change; incidence of
tuberculosis, cryptococcosis, candidiasis, severe bacterial infections); changes in weight/BMI;
hospitalisations; and self-reported ART adherence/acceptability. Other prespecified outcomes
included VL suppression (originally planned to be assayed only in a random subset; ultimately
assayed in all participants), genotypic resistance (assayed in samples from Kenya, Uganda, and
Zimbabwe, see S1 Text), and body composition. All AEs were graded following established
guidelines [20,21]. HIV integrase genotypes were assayed for raltegravir-intensified partici-
pants with VL>1,000 c/mL at 12 weeks, and reverse transcriptase genotypes were assayed for
all participants with VL>1,000 c/mL at 48 weeks. An Endpoint Review Committee (ERC)
(majority independent members), blind to trial drugs received, adjudicated secondary clinical
endpoints and trial-drug relatedness against protocol-defined criteria and assessed compatibil-
ity of clinical events with IRIS. Clinical endpoints were predominantly clinically defined, as
microbiological and other diagnostic facilities were limited in most centres. Because of this
known limitation, IRIS was not a secondary outcome and was considered an exploratory anal-
ysis. However, IRIS was part of the standardised ERC assessment and ERC case record form
from the start of the trial and was prospectively ascertained on all reviewed events. Events were
considered IRIS compatible if there was atypical or exaggerated presentation of an opportunis-
tic infection or tumour soon after ART initiation. VLs were only measured retrospectively on
stored plasma and so were not available contemporaneously for assessment of IRIS compatibil-
ity; the earliest post-randomisation CD4 count was done at 4 weeks and so was not available
for events before this. As access to diagnostic testing was limited, previously published defini-
tions [22,23] were used but in modified form; the ERC adjudication relied heavily on the
description of the clinical presentation and any radiology/microbiology/histology provided by
site, and the timing of the presentation and its evolution in relation to ART initiation.
A total of 1,800 adults/children provided >80% power to detect 50% relative reductions in
24-week all-cause mortality from 7% to 3.5% (two-sided alpha = 0.05), allowing 5% lost to fol-
low-up. Interim data were reviewed by an independent Data Monitoring Committee (three
annual meetings) using the Haybittle-Peto criterion (p< 0.001). Randomised groups were
compared following the intention to treat principle using log-rank tests for time-to-event out-
comes (censoring those lost to follow-up), Fisher exact tests for binary outcomes, and general-
ized estimating equations (GEEs) with independent working correlation for global tests of
repeated measures (logit/normal distributions for binary/continuous outcomes, respectively).
Primary analyses were stratified by randomisation stratification factors (details in S1 Text).
Analyses used Stata v15.1.
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Results
Between 18 June 2013 and 10 April 2015, 1,805 participants were randomised to standard
ART (n = 903) or raltegravir-intensified ART (n = 902) (Fig 1).
Baseline characteristics were well balanced between randomised groups (Table 1). Median
age was 36 years; 72 (4.0%) participants were aged 5–17 years. Median CD4 count was 37 cells/
mm3 and VL was 249,770 copies/mL; 1,334/1,804 (73.9%) had VL� 100,000 copies/mL.
Despite this, 854 (47.3%) participants were WHO stage 1/2. A total of 56 (3.1%) participants
were lost to follow-up (no clinic attendance for>91 days). Before death/loss to follow-up,
12,664/12,944 (97.8%) scheduled visits were completed.
Randomised interventions
A total of 901 (99.9%) participants randomised to raltegravir-intensified ART were prescribed
raltegravir. Overall, in the first 12 weeks on ART the raltegravir-intensified ART group spent
98.2% of person-time prescribed raltegravir versus 0.0% in the standard ART group, compared
with 0.6% versus 0.1%, respectively, from 12 to 48 weeks (S1 Fig). Self-reported ART adher-
ence was high but was significantly poorer in the raltegravir-intensified ART group during the
first 12 weeks only (p< 0.001) (overall p = 0.08, S2A Fig), particularly in those taking other
ART once daily (S2B Fig). At last follow-up, 885 (98.0%) standard ART versus 880 (97.6%) ral-
tegravir-intensified ART participants remained on first-line ART (exact p = 0.53), with 67
(7.4%) standard ART versus 52 (5.8%) raltegravir-intensified ART participants having made
within-class substitutions (exact p = 0.18).
VL suppression
Despite slightly poorer self-reported adherence, early VL suppression was significantly and
substantially faster with raltegravir intensification (Fig 2A), with 41.0% (343/836), 71.9% (567/
789), 76.7% (594/774), and 80.7% (661/757) participants, respectively, recording <50 copies/
mL 4, 12, 24, and 48 weeks after randomisation versus 13.4% (113/841), 51.7% (415/803),
74.7% (586/784), and 79.2% (591/746) in the standard ART group, respectively (p< 0.001,
p< 0.001, p = 0.36, and p = 0.47, respectively). Overall, therefore, 59.4% versus 43.6% of time
at risk through 24 weeks was spent with VL<50 copies/mL in raltegravir-intensified versus
standard ART, respectively. At higher thresholds, differences at week 4 were even greater and
attenuated more rapidly but persisted through 24 weeks (S3 Fig). At 48 weeks, there was no
evidence of differential suppression at 50–5,000 copies/mL (p> 0.4). Mean change in log10 VL
to week 4 was −3.4 (standard error [SE] 0.03) versus −2.7 (SE 0.03) in raltegravir-intensified
ART versus standard ART (p< 0.001), with geometric mean VL 80 c/mL and 480 c/mL,
respectively.
Mortality
By 24 weeks (primary endpoint), 97 (10.9%) raltegravir-intensified ART versus 91 (10.2%)
standard ART participants died (adjusted hazard ratio [aHR] = 1.10 [95% CI 0.82–1.46], log-
rank p = 0.53, Fig 3A), with no evidence of interaction with other randomisations (pheterogeneity
> 0.7). Absolute 24-week mortality difference was +0.6% (−2.2%, +3.5%). By 48 weeks, 110
(12.4%) versus 115 (13.0%) participants, respectively, had died (aHR = 0.98 [0.76–1.28], log-
rank p = 0.91; absolute difference −0.6% [−3.7%, +2.5%]) with no evidence of differences by
cause (Table 2). There was no difference in longer-term (after week 48) mortality (aHR = 0.95
[0.74–1.21], log-rank p = 0.69, S4 Fig). Estimated mortality rates decreased sharply from day
19 through week 12 (Fig 3B), with 71 (31.6%) of the 225 deaths occurring by 4 weeks, and 147
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(65.3%) by 12 weeks. There was no evidence of early differences in mortality rates (S5 Fig)
and no evidence of heterogeneity in the impact of raltegravir intensification over time on ART
(pheterogeneity = 0.14, comparing 0–24 versus 24–48 versus 48+ weeks on ART). Of nine pre-
planned and five exploratory subgroup analyses (S6 Fig; details in S1 Text), only one had weak
evidence for variation across dual NRTIs (pheterogeneity = 0.04, suggesting harm from raltegravir
Fig 1. Trial profile. ART, antiretroviral therapy; CD4, cluster of differentiation 4; RUSF, ready-to-use supplementary
food.
https://doi.org/10.1371/journal.pmed.1002706.g001
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intensification in combination with tenofovir-emtricitabine; pheterogeneity = 0.06 comparing
tenofovir-emtricitabine versus zidovudine-lamivudine [excluding abacavir-lamivudine]). Spe-
cifically, there was no evidence that mortality differences depended on pre-ART VL or pre-
ART CD4 (pheterogeneity = 0.84/0.49 and 0.22/0.27, respectively, using categorical/continuous
interactions). No subgroup analyses suggested heterogeneity in the impact of raltegravir inten-
sification on suppression <50 copies/mL at week 4 (pheterogeneity > 0.05) (S7 Fig).
Table 1. Characteristics at enrolment.
Factor Standard ART
(N = 903)
Raltegravir-intensified
(N = 902)
All
(N = 1,805)
Male 482 (53.4%) 479 (53.1%) 961 (53.2%)
Age at last birthday (years) 36 (29–42) [5–77] 35 (29–42) [6–72] 36 (29–42) [5–77]
5–17 years 33 (3.7%) 39 (4.3%) 72 (4.0%)
HIV VL (c/mL) (N = 1,804) 250,000
(95,450–631,560)
246,700
(94,000–578,080)
249,770
(95,280–606,360)
�100,000 c/mL 667/902 (73.9%) 667/902 (73.9%) 1,334/1,804 (73.9%)
<1,000 c/mL�� 7/902 (0.8%) 7/902 (0.8%) 14/1,804 (0.8%)
CD4 count� (cells/mm3) 36 (16–61) 38 (16–64) 37 (16–63)
0–24 cells/mm3 335 (37.1%) 321 (35.6%) 656 (36.3%)
25–49 cells/mm3 256 (28.3%) 253 (28.0%) 509 (28.2%)
Weight� (kg) (N = 1,800) 52.9 (46.7–59.8) 52.3 (45.8–59.0) 52.5 (46.3–59.3)
BMI (kg/m2) (N = 1,797) 19.3 (17.5–21.6) 19.0 (17.1–21.2) 19.2 (17.2–21.4)
<18 kg/m2 302/900 (33.6%) 323/897 (36.0%) 625/1,797 (34.8%)
WHO stage
1 145 (16.1%) 155 (17.2%) 300 (16.6%)
2 290 (32.1%) 264 (29.3%) 554 (30.7%)
3 341 (37.8%) 350 (38.8%) 691 (38.3%)
4 127 (14.1%) 133 (14.7%) 260 (14.4%)
Current tuberculosis disease 137 (15.2%) 134 (14.9%) 271 (15.0%)
Haemoglobin (g/L) (N = 1,800) 112 (96–127) 111 (95–127) 112 (96–127)
�80 g/L 86 (9.6%) 90 (10.0%) 176 (9.8%)
NRTIs
Tenofovir/emtricitabine 719 (79.6%) 703 (77.9%) 1,422 (78.8%)
Zidovudine/lamivudine 154 (17.1%) 169 (18.7%) 323 (17.9%)
Abacavir/lamivudine 30 (3.3%) 30† (3.3%) 60 (3.3%)
NNRTI
Efavirenz 816‡ (90.4%) 803 (89.0%) 1,619 (89.7%)
Nevirapine 87 (9.6%) 99 (11.0%) 186 (10.3%)
Randomised to receive enhanced anti-infection prophylaxis 451 (49.9%) 455 (50.4%) 906 (50.2%)
Randomised to receive RUSF 449 (49.7%) 448 (49.7%) 897 (49.7%)
�Mean of screening and enrolment values. Eligibility required screening CD4 to be <100 cells/mm3, so baseline can be above 100, depending on the CD4 at enrolment.
��Potentially indicating undisclosed prior ART: median CD4 was 76 cells/mm3 in these participants.
†One child was mistakenly initiated on Aluvia (lopinavir/ritonavir) rather than abacavir/lamivudine (plus efavirenz and raltegravir); substituted with abacavir/
lamivudine after 4 weeks.
‡One adult took tenofovir/emtricitabine alone for 4 days in error before adding efavirenz on day 4.
Note: Showing n (%) or median (IQR) [range].
Abbreviations: CD4, cluster of differentiation 4; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; RUSF, ready-
to-use supplementary food; VL, viral load.
https://doi.org/10.1371/journal.pmed.1002706.t001
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Other clinical efficacy outcomes
There was no evidence of an impact of raltegravir intensification on any disease progression
clinical outcome (Table 2).
Genotypic resistance
Integrase genotypes were obtained in 33 raltegravir-intensified ART participants with VL
>1,000 (median 47,724) copies/mL at 12 weeks (see S2 Text). One participant had predicted
intermediate-level (mutations T97A+R263K) and two predicted high-level (N155H, T97A+-
Y143R/C) raltegravir resistance mutations (0.6% of those randomised, accounting for missing
genotypes using probability weights). No patient had predicted intermediate- or high-level
dolutegravir resistance.
Reverse-transcriptase genotypes were available for 75 raltegravir-intensified ART versus 87 stan-
dard ART participants with VL>1,000 (median 89,815) copies/mL at 48 weeks. The NRTI muta-
tion K219E/Q (p = 0.004) and the NNRTI mutations K101E/P (p = 0.03) and P225H (p = 0.007)
were less common in raltegravir-intensified ART, with no evidence of differences for other muta-
tions (p> 0.1, S8 Fig). There was marginal evidence suggesting less intermediate- or high-level
resistance with raltegravir-intensified ART to tenofovir (24.0% [18/75] raltegravir-intensified ART
versus 37.9% [33/87] standard ART, p = 0.06), abacavir (40.0% [30/75] raltegravir-intensified ART
versus 54.0% [47/87] standard ART, p = 0.08), and rilpivirine (38.7% [29/75] raltegravir-intensified
ART versus 52.9% [46/87] standard ART, p = 0.07) (S9 Fig) (see S2 Text for details).
CD4 and CD8 count and body composition
Absolute CD4 count increases were similar in both groups through 24 weeks (p = 0.76; Fig
2B); however, there was marginal evidence of a small difference at 48 weeks (+161 [standard
deviation ±4.4] cells/mm3 raltegravir-intensified ART versus +148 [±4.4] cells/mm3 standard
ART, adjusted difference +11.4 [95% CI −0.4 to +23.1], p = 0.06). There was similar weak evi-
dence of slightly (2%–5%) greater percentages with CD4� 200 cells/mm3 at later time points
(p = 0.049 at week 24, p = 0.07 at week 48, S10 Fig). Changes in weight were also similar
through week 24 (p = 0.52; Fig 2C), with small but significant differences appearing from 36–
48 weeks. Similar late differences were observed for BMI in adolescents/adults (data not
shown), fat mass (S11A and S11B Fig), and muscle mass (S11C and S11D Fig). There was no
evidence of heterogeneity in these differences by age (S12 Fig). Absolute CD8 count increases
were similar in both groups through 48 weeks (p = 0.82, S13 Fig).
Safety outcomes
There was no evidence for differences in time to first SAEs (log-rank p = 0.88; S1 Table),
grade-4 AEs (log-rank p = 0.29), grade-3/4 AEs (log-rank p = 0.72), grade-4 AEs definitely/
probably/possibly related to ART (log-rank p = 0.52), grade-4 AEs definitely/probably related
to ART (log-rank p = 0.07), AEs leading to ART modification (log-rank p = 0.51) or new hos-
pitalisations (log-rank p = 0.59) (Table 2). Raltegravir was modified for AEs in 19 (2.1%) par-
ticipants (S2 Table), including renal (n = 6) events, hepatic (n = 6) events, hypersensitivity
reactions (n = 3; two discontinued with efavirenz, which was subsequently restarted; one dis-
continued with tenofovir+emtricitabine+efavirenz, subsequently started lopinavir+ritonavir
+tenofovir+emtricitabine+raltegravir), and Stevens-Johnson syndrome in one participant
Fig 2. HIV viral load, CD4 cell count, and weight. ART, antiretroviral therapy; CD4, cluster of differentiation 4; VL,
viral load.
https://doi.org/10.1371/journal.pmed.1002706.g002
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Fig 3. Mortality. ART, antiretroviral therapy; PY, person-years.
https://doi.org/10.1371/journal.pmed.1002706.g003
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(discontinued lamivudine+zidovudine+efavirenz+raltegravir at week 7). Only one participant
experienced a grade-4 AE adjudicated as definitely/probably related to raltegravir (Table 2).
There was no evidence of any difference in total hospitalisation-days (2,367 raltegravir-intensi-
fied ART versus 2,685 standard ART, rank-sum p = 0.56) or total hospitalisations (198 versus
233, respectively, Poisson p = 0.09).
IRIS (exploratory analysis)
Fatal or nonfatal events judged compatible with IRIS occurred in 89 (9.9%) raltegravir-intensi-
fied ART versus 86 (9.5%) standard ART participants (log-rank p = 0.79) (Table 2); 36 (4.0%)
Table 2. Secondary and other clinical outcomes through 48 weeks.
Outcome Standard ART
N participants (% of 903)
[events]
Raltegravir-intensified
ART
N participants (% of 902)
[events]
Total
N participants (% of 1,805)
[events]
Hazard ratio†
(95% CI)
p
Death� 115 (13.0%) [115] 110 (12.4%) [110] 225 (12.5%) [225] 0.98 (0.76, 1.28) 0.91
- from tuberculosis 24 (2.7%) [24] 18 (2.0%) [18] 42 (2.3%) [42] 0.75 (0.40, 1.37)† 0.35
- from cryptococcal disease 6 (0.7%) [6] 11 (1.2%) [11] 17 (0.9%) [17] 1.84 (0.68, 4.97)† 0.23
- from severe bacterial infections 16 (1.8%) [16] 17 (1.9%) [17] 33 (1.8%) [33] 1.07 (0.54, 2.11)† 0.86
- from other causes 23 (2.5%) [23] 22 (2.4%) [22] 45 (2.5%) [45] 0.96 (0.53, 1.71)† 0.88
- cause unknown 46 (5.1%) [46] 42 (4.7%) [42] 88 (4.9%) [88] 0.91 (0.60, 1.38)† 0.66
New WHO 4 event or death 164 (18.2%) [216] 155 (17.2%) [203] 319 (17.7%) [419] 0.97 (0.77, 1.20) 0.75
New WHO 3 or 4 event or death 197 (21.8%) [310] 206 (22.8%) [301] 403 (22.3%) [611] 1.08 (0.89, 1.31) 0.44
New tuberculosis disease� 80 (8.9%) 103 76 (8.4%) 93 156 (8.6%) [196] 0.95 (0.70, 1.31) 0.77
New cryptococcal disease� 18 (2.0%) 25 14 (1.6%) 26 32 (1.8%) [51] 0.78 (0.38, 1.58) 0.49
New candida disease� 16 (1.8%) 18 17 (1.9%) 18 33 (1.8%) [36] 1.06 (0.54, 2.11) 0.86
New presumptive severe bacterial infection� 33 (3.7%) 49 42 (4.7%) 62 75 (4.2%) [111] 1.28 (0.81, 2.02) 0.28
IRIS 86 (9.5%) [89] 89 (9.9%) [91] 175 (9.7%) [180] 1.04 (0.78, 1.40) 0.79
Any SAE� 207 (22.9%) 287 203 (22.5%) 251 410 (22.7%) [538] 0.99 (0.81, 1.21) 0.88
New hospitalisation� 175 (19.4%) [233] 165 (18.3%) [198] 340 (18.8%) [431] 0.94 (0.76, 1.17) 0.59
Grade-4 AE� 188 (20.8%) [267] 165 (18.3%) [237] 353 (19.6%) [504] 0.88 (0.71, 1.09) 0.29
Grade-3 or -4 AE 327 (36.2%) [550] 331 (36.7%) [503] 658 (36.5%) [1053] 1.03 (0.88, 1.20) 0.72
Grade-4 AE definitely, probably, or possibly
related to ART
67 (7.4%) [73] 59 (6.5%) [65] 126 (7.0%) [138] 0.89 (0.63, 1.27) 0.52
Grade-4 AE definitely or probably related to
ART
28 (3.1%) [28] 16 (1.8%) [18] 44 (2.4%) [46] 0.57 (0.31, 1.06) 0.07
AE leading to ART modification� 66 (7.3%) [73] 59 (6.5%) [66] 125 (6.9%) [139] 0.90 (0.63, 1.27) 0.54
Grade-4 AE definitely, probably, or possibly
related to raltegravir
- 31 (3.4%) [34] - -
Grade-4 AE definitely or probably related to
raltegravir
- 1‡ (0.1%) [1] - -
AE leading to raltegravir modification - 19 (2.1%) [19] - -
�Secondary outcome prespecified in the protocol.
†For causes of death, competing risks subhazard ratio accounting for other causes of death.
‡Stevens-Johnson syndrome that was adjudicated as definitely/probably related to efavirenz, raltegravir, and co-trimoxazole and possibly related to fluconazole,
tenofovir, and emtricitabine.
Note: Table shows number of patients with one or more episode (percentage of patients) [number of episodes] (e.g., ‘2 (20.0%) [3]’ would indicate a total of three
episodes in two patients). No evidence of interaction with other factorial randomisations (pheterogeneity > 0.1; 34 tests; testing not conducted for grade-4 AE definitely or
probably related to raltegravir as only one event).
Abbreviations: AE, adverse event; ART, antiretroviral therapy; IRIS, immune reconstitution inflammatory syndrome; SAE, serious adverse event.
https://doi.org/10.1371/journal.pmed.1002706.t002
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versus 31 (3.4%), respectively, experienced fatal IRIS events (p = 0.54). Tuberculosis IRIS
events occurred in 53 (5.9%) participants with raltegravir-intensified ART versus 54 (6.0%)
with standard ART (exact p = 1.00) and cryptococcal IRIS events in 15 (1.7%) versus 16 (1.8%)
participants, respectively (exact p = 1.00) (S3 Table). IRIS events occurred a median 3.4 (IQR
2.0–6.3) weeks from randomisation, with rates declining from the third week on ART (S14
Fig). IRIS was more common in participants initiating ART at older ages (p = 0.005), with
lower CD4 counts (p< 0.001) or with pre-existing TB (p = 0.007); IRIS was less common in
those initiating ART with enhanced prophylaxis against opportunistic infections (p = 0.001)
(S4 Table). There was no evidence that raltegravir intensification was associated with IRIS
after adjusting for these factors (p = 0.63).
Discussion
In this large trial in adults and older children with CD4<100 cells/mm3 in sub-Saharan Africa,
we found that 12-week raltegravir intensification of standard ART was well tolerated and
reduced plasma HIV VL substantially faster than standard ART alone, but that this had no dis-
cernible clinical benefit and no effect on mortality; however, nor was there any evidence of
increased rates of IRIS. This is important given the current move to first-line INSTI-based
ART; all INSTIs have similarly rapid VL reductions [24], so this result can likely be extrapo-
lated to other INSTIs.
The underpinning hypothesis was that mortality might be reduced by accelerating plasma
HIV RNA decline with INSTIs, because initiating ART reduces mortality compared with rates
observed pre-ART [25]. One reason this did not occur could be that the differential VL sup-
pression, although significant and substantial, was still too small to reduce mortality. As VL
reductions are similar across INSTIs [24], other INSTIs would likely produce similar results.
Other explanations for lack of mortality benefit despite significantly faster VL declines may be
because there was a lag in, or no, improvement in early functional CD4 recovery or because
the disease may simply have been too severe to be reversed despite rapid VL decline. CD4 and
CD8 T cells were the only markers of immune restoration measured in real time in all partici-
pants, so we cannot investigate further; but there was no differential effect on CD4 (or CD8)
counts, at least in the first 24 weeks. This might be expected, as immune restoration does not
only depend on HIV viraemia driving inflammation and T-cell turnover [26]. What is intrigu-
ing in this context is the small but significant difference in CD4 count at week 48 following
only 12 weeks’ raltegravir intensification, which is consistent with previous findings of mod-
estly greater longer-term CD4 increases in HIV seroconverters initiating integrase-inhibitor-
containing ART [27] and the STARTMRK trial [28]. We are unable to explore whether CD4
immune restoration continued to diverge after 48 weeks to larger, more clinically relevant dif-
ferences [29] but plan to measure inflammatory biomarkers [30,31], T-cell subsets, and mark-
ers of T-cell turnover and activation in a subset of participants in whom peripheral blood
mononuclear cells were stored. However, our results do suggest that quadruple ART is unlikely
to provide any clinical benefit over standard triple-drug ART in patients with VL>100,000
copies/mL or advanced disease. Furthermore, the lack of evidence of clinical benefit does not
support evaluation of adjunctive INSTIs in less immunocompromised patients, whose risk of
clinical events is markedly lower [5].
With increasing moves towards replacing NNRTIs with INSTIs in first-line ART, findings
from retrospective observational studies [32,33] have raised major concerns regarding the
potential for increased IRIS events with faster VL declines, which may have particularly impor-
tant consequences in severely immunocompromised patients and where CD4 counts may no
longer be available, so that closer clinical monitoring cannot be instigated. Our randomised
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trial found no evidence of higher rates of clinical IRIS events associated with the significantly
faster VL declines with raltegravir-intensified ART. This finding also has relevance for the
increasing numbers of treatment-experienced patients returning after previous disengagement
from care [34], for whom INSTIs are an attractive option given challenges in accessing resis-
tance testing. Whilst unaffected by raltegravir intensification, IRIS events were significantly
reduced by the enhanced-prophylaxis bundle also investigated in this trial [35].
One potential benefit from faster declines in VL is reduced potential for onward transmis-
sion, particularly because almost half of the trial participants had minimal symptoms (WHO
stage 1 or 2). However, the differential suppression occurred between weeks 4 and 12, with
overall only 15.8% less time spent with VL <50 c/mL in the standard ART group through
week 24 (albeit predominantly at the time of greatest risk of clinical events). Therefore, benefits
at a population level would likely be modest at best. However, such a strategy might have par-
ticular value in swiftly reducing VL in women identified as HIV-infected during pregnancy to
reduce mother-to-child transmission [36].
Poorer compliance with raltegravir-intensified ART could explain the lack of clinical bene-
fit, although the substantial differences in early VL suppression suggest that adherence to ralte-
gravir-intensified ART was reasonable. However, the additional twice-daily raltegravir pill
reduced self-reported adherence to ART in participants receiving other ART once daily by
about 4% (S2B Fig). Association with twice-daily dosing, rather than pill burden, is supported
by the lack of difference in self-reported ART adherence between participants randomised in
this trial to enhanced-prophylaxis versus standard-of-care co-trimoxazole (one additional pill
once daily from day 5 to 12 weeks) [17]. Although the induction of UGT1A1 by efavirenz
(reducing raltegravir levels by about one third) and/or incomplete adherence in those on
twice-daily regimens might have reduced efficacy, there was no evidence of heterogeneity in
VL suppression at week 4, or mortality, according to initial NNRTI or according to whether
other ART was once daily versus twice daily.
At 48 weeks, 20.0% of participants had a VL�50 copies/mL and 12.6% had�1,000 copies/
mL; this may be unsurprising given advanced disease at ART initiation but limits power to
investigate drug resistance. Despite similar rates of virological failure�1,000 copies/mL, ralte-
gravir-intensified ART was associated with lower rates of the NRTI mutation K219E/Q and
the NNRTI mutations K101E/P and P225H. A limitation is that we did not assay samples at
ART initiation; however, randomising large numbers should provide balance between ralte-
gravir-intensified ART and standard ART in transmitted drug resistance. This may suggest
that these specific mutations arise early in treatment and, even if then suppressed, ultimately
re-emerge at failure. However, differences in predicted NRTI/NNRTI resistance were at most
marginal for tenofovir, abacavir, and rilpivirine, and raltegravir intensification did not sub-
stantially protect against developing clinically meaningful NRTI/NNRTI resistance. Major
integrase mutations potentially compromising raltegravir occurred in very small numbers and
did not preclude future use of dolutegravir.
The trial’s major strengths were the mortality primary endpoint in a well-defined high-risk
population from eight HIV clinics across four African countries, increasing generalisability.
Limitations include the fact that some WHO 3/4 and IRIS events were probably misclassified
due to limited clinical, radiological, and/or microbiological information for some participants,
reflecting available services at the centres, meaning we were also unable to accurately distin-
guish between IRIS-associated unmasking versus new active disease. Furthermore, the first
post-randomisation CD4 was done at 4 weeks only and VL data were retrospective and not
available for review. However, adjudications were made blinded to trial drugs, minimising bias
in the overall findings, and the primary endpoint, 24-week mortality, was completely objective.
IRIS rates were lower than some previous studies but likely included most clinically important
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events. Ultimately, the trial was well powered to detect differences in mortality, providing con-
fidence that even if some IRIS events were missed, these were not leading to excess deaths
given the relatively tight 95% CI around absolute mortality differences. We did not assess VL
response before 4 weeks (first stored sample), when one third of the deaths had already
occurred. We were unable to genotype Malawian samples (12.5% of the participants) and
obtained integrase genotypes in only 73% of samples with VL >1,000 copies/mL at 12 weeks,
possibly because of challenges with primers for non-clade-B viruses. We recruited fewer chil-
dren than planned, limiting our ability to assess effects in this subgroup.
Overall, REALITY trial findings do not support intensification of ART with the INSTI, ral-
tegravir, for the first 12 weeks in severely immunocompromised adults and children infected
with HIV. In contrast, the enhanced prophylaxis bundle also tested in the REALITY trial pro-
vided substantial reduction in both mortality [17] and morbidity (including IRIS) [35] and
could also be practically implemented at primary care level, provided CD4 counts were available
to identify those at risk. Successful future interventions would need to improve both the rapidity
and functional quality of immunological recovery and/or reduce inflammation and/or further
improve prevention and management of IRIS. Earlier diagnosis and initiation of lifelong ART
should continue to be a major focus, particularly in sub-Saharan Africa, as, despite recommen-
dations for universal ART, the proportion of ‘late presenters’ appears to have plateaued in both
low- and middle-income countries [37] and high-income countries [38], suggesting that sub-
stantial numbers will continue to present late for care in low- and middle-income countries for
the foreseeable future. Finally and importantly, this study provides no evidence that moving to
INSTIs as part of standard first-line therapy, as currently planned across many low- and mid-
dle-income countries, will increase rates of clinically important IRIS in such individuals.
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